Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Capecitabine After Salvage Surgery in Head and Neck Cancer
NCT00095641Phase 2Withdrawn
- Sponsor
- SWOG Cancer Research Network
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of capecitabine in squamous cell carcinoma of the head and neck (HNSCC), sponsored by SWOG Cancer Research Network. Status: withdrawn.
02
Drugs
capecitabine
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00095641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095641.